Victory Capital Management Inc. recently announced a boost in its holdings of Masimo Corporation ($NASDAQ:MASI) stock, reflecting the investment firm’s confidence in the medical equipment provider’s future growth. Masimo Corporation is a global medical technology company that develops and manufactures innovative non-invasive patient monitoring technologies. These products include the company’s flagship noninvasive hemoglobin monitor, Masimo SET, as well as Masimo rainbow SET, which measure multiple blood constituents. Masimo also provides several other products such as Masimo NomoLine, an in-hospital patient monitoring system; Masimo NomoLine Pro, a single-patient bedside monitor; and Masimo SmartSuite, a suite of software applications designed to help hospitals streamline their operations.
The boost in Victory Capital Management’s holdings of Masimo Corporation stock is seen as a sign of confidence in the company’s products and potential for future growth. The announcement is expected to have a positive impact on Masimo’s stock price, which could attract additional investors to the company’s stock. With the rise in the stock price, Masimo Corporation could benefit from increased resources to further develop its offerings and expand its reach to new markets.
On Monday, Masimo Corporation stock opened at $119.9 and closed at $123.0, up by 2.5% from the previous closing price of 120.0. This move by Victory Capital Management Inc. indicates their trust in Masimo Corporation’s potential to deliver long-term profits for their investors. With this positive boost in stock prices, the team at Masimo Corporation is likely to be pleased and encouraged as they move forward with their plans. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Masimo Corporation. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Masimo Corporation. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Masimo Corporation. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Masimo Corporation are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we recently conducted an analysis of MASIMO CORPORATION‘s fundamentals. Our Star Chart gave MASIMO CORPORATION a high health score of 8/10 with regard to its cashflows and debt, suggesting that it is capable of safely riding out any crisis without the risk of bankruptcy. In terms of growth, profitability, assets and dividend, MASIMO CORPORATION scored high, medium and weak respectively. Based on this data, we classified MASIMO CORPORATION as a ‘gorilla’ – a company that has achieved stable and high revenue or earning growth due to its strong competitive advantage. Given this company’s strong performance in financially volatile times, we believe that it would be an attractive investment option for many investors. Long-term value investors may be drawn to its strong cash flows and debt ratings, while active traders may be interested in its strong growth prospects. All in all, MASIMO CORPORATION is a company well-suited for a variety of investors. More…
Risk Rating Analysis
Star Chart Analysis
In the medical device industry, there is intense competition between Masimo Corp and its rivals Elekta AB, Essilorluxottica, and Compumedics Ltd. While all four companies offer innovative products and services, each has its own unique strengths and weaknesses. As a result, the competition between them is fierce, and it is often difficult for one company to gain a significant advantage over the others.
Despite a challenging year for the company, Elekta’s market cap has grown to 2.09B as of 2022. This is due in part to the company’s strong return on equity, which stands at 11.86%. Elekta is a leading provider of radiation therapy solutions for the treatment of cancer. The company’s products are used in over 6,000 hospitals and clinics around the world, and its solutions are backed by a team of over 3,000 employees.
– Essilorluxottica ($LTS:0OMK)
EssilorLuxottica is a French-Italian multinational corporation that designs, manufactures, and markets ophthalmic lenses, instruments, and equipment. The company has a presence in over 130 countries and employs more than 140,000 people. The company was formed in 2018 through the merger of Essilor International and Luxottica.
– Compumedics Ltd ($ASX:CMP)
Computedics Ltd is a technology company that provides computing and analytics solutions. The company has a market cap of 42.52M as of 2022 and a Return on Equity of 1.53%. Computedics Ltd provides computing and analytics solutions to businesses and organizations worldwide. The company offers a range of services, including data storage, cloud computing, data analysis, and security. Computedics Ltd is headquartered in Sydney, Australia.
Victory Capital Management Inc. has recently increased its holdings in Masimo Corporation, indicating confidence in the medical equipment provider’s potential for growth. The investment management firm has seen dramatic growth in their Masimo Corporation investments and believes the company is well-positioned for success in the industry. Victory Capital has based this decision on extensive research and analysis, demonstrating the company’s stability and strength.
Through an expected increase in demand for medical equipment, Masimo Corporation is positioned to capitalize on its current offerings. Victory Capital has strategically chosen to invest in the firm’s long-term prospects, recognizing the potential for growth and expansion in the near future.